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ABSTRACT 
 
About three percent of all HTLV-1 infected individuals will develop a disabling inflammatory 
disease of the central nervous system known as HTLV-1 Associated Myelopathy / Tropical 
Spastic Paraparesis, against which there is currently no efficient treatment. As correlation 
exists between the proviral load (PVL) and the clinical status of the carrier, it is believed that 
diminishing the PVL could prevent later occurrence of the disease. We have conducted a 
study combining valproate (VPA), an inhibitor of histone deacetylases (HDACi), and AZT, 
an inhibitor of reverse transcriptase, in a series of baboons naturally infected with STLV-1, 
whose PVL was equivalent to that of HTLV-1 ACs. We show that the combination of drugs 
caused a strong decrease in the PVL and prevented the transient rise in PVL that is seen after 
treatment with HDACi alone. We then demonstrate that the PVL decline was associated with 
an increase in the STLV-1-specific cytotoxic T-cell population. We conclude that combined 
treatment with VPA to induce viral expression and AZT to prevent viral propagation is a safe 
and effective means to decrease PVL in vivo. Such treatments may be useful to reduce the risk 
of HAM/TSP in ACs with a high PVL. 
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INTRODUCTION 
 Ten to 20 million people are infected with human T-Lymphotropic Virus type 1 
(HTLV-1) worldwide. This retrovirus is the etiological agent of a malignant 
lymphoproliferative disease called Adult T-cell Leukemia / Lymphoma (ATLL) 1,2, and of 
several inflammatory diseases, particularly of HTLV-1 Associated Myelopathy / Tropical 
Spastic Paraparesis (HAM/TSP) 3-5. Despite numerous clinical trials, no efficient treatment 
has yet been described for HAM/TSP patients. HAM/TSP is a neurodegenerative disease with 
major irreversible demyelination and loss of motor neurones from the pyramidal tract 6-11 and 
the current treatments can only stabilize the clinical status of the patient. It is therefore 
necessary to develop therapies that can prevent the occurrence of this virus-associated 
neurodegenerative disease or at least block the evolution of the disease in the early stages of 
the pathogenesis. 
HTLV-1 infects a wide range of cells in vitro. However, in vivo, it is principally detected in 
CD4+ T-lymphocytes, and to a lesser extent CD8+ cells 12-16. Importantly, there is an 
association between the HTLV-1 proviral load (PVL) and the clinical status of the 
individuals. The PVL measured in the peripheral mononuclear cells (PBMCs) isolated from 
HAM/TSP patients is 5 to 20-fold higher than that of asymptomatic carriers (ACs) 17-21. 
Similarly, HLA genotypes associated with a low PVL are associated with a reduced risk of 
HAM/TSP 22,23. It is therefore likely that the PVL in an AC will predict the risk of developing 
an HTLV-1 related disease. In ACs with a high proviral load, diminishing the PVL may also 
prevent later occurrence of the disease. 
 Most cells infected with HTLV-1 appear transcriptionally-silent at a given time, which 
makes therefore viral expression difficult to detect in vivo in ACs even when using highly 
sensitive techniques such as RT-PCR 24,25. It is known that the virus replicates mostly, during 
the chronic phase of infection, via clonal expansion of the infected cells 26. This pseudo-
 4 
latency renders HTLV-1 resistant to antiretroviral drug treatments in vivo such as AZT, and is 
likely to play an important role in viral escape from the host immune response 24,27. As with 
cellular genes, the expression of the HTLV-1 provirus is epigenetically regulated and the low 
level of viral expression is associated with proviral chromatin deacetylation and condensation 
28,29
. A transient transcriptional activation of the viral reservoir should therefore allow a 
reduction of the PVL in vivo, as long as the host maintains an efficient antiviral immune 
response.  
 A recent in vitro study demonstrated that treating HTLV-1 infected lymphocytes with 
valproate (VPA), an inhibitor of histone deacetylases (HDACi), induces viral expression and 
cell death 30,31. A clinical trial with VPA was then initiated in a series of 16 HAM/TSP 
patients at a late development stage of the disease 9. This led to a decrease of the PVL after 45 
to 60 days of treatment 9,32. Unfortunately no significant improvement was observed in the 
clinical status of the patients, perhaps because the HTLV-1-associated neurological damage 
had already taken place, or because a longer follow-up period was necessary. Moreover, a 
transient PVL rise was consistently observed in the first weeks of the treatment, probably due 
to the induction of HTLV-1 proviral expression by VPA and subsequent infectious 
propagation. Since PVL is linked to disease progression, this observation represents a major 
concern that currently prevents further use of VPA-based therapy 33. In this study, the PVL 
rise was associated with an increase in the 8-meter walking time. It was also pointed out that, 
in theory, the transient PVL peak might favor CNS invasion (and thus worsen inflammation), 
as it potentially increases the probability that an HTLV-1 infected lymphocyte will cross the 
blood-brain barrier 32. Therefore, preventing the PVL increase at the initiation of treatment 
should be beneficial in the long term. This trial suggested that VPA might constitute an 
effective means to prevent or treat HAM/TSP if one could prevent the initial viral replication.  
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 We therefore conducted a study combining VPA and AZT, an inhibitor of the reverse 
transcriptase, in a series of baboons (Papio papio) naturally infected with Simian T-
Lymphotropic Virus type 1 (STLV-1). STLV-1 is the simian counterpart of HTLV-1. The two 
viruses are almost identical at the nucleotide sequence level. Baboons constitute an interesting 
but little-used model of asymptomatic HTLV-1 infection 34: their immune system is very 
similar to the human, the animals are naturally infected with STLV-1, and some develop 
STLV-1-associated diseases such as ATLL 35. We report here that the VPA/AZT combined 
treatment induced a strong decrease in the PVL in treated animals and prevented the transient 
rise in PVL observed after treatment with HDACi alone. The PVL decline was correlated 
with an increase in the STLV-1-specific cytotoxic T-cell population.  
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METHODS 
Animal treatment 
 Fourteen baboons (Papio papio), naturally infected with STLV-1, were included in 
this study. Animals were housed at the primate center of the CNRS in Rousset-sur-Arc and 
cared for in compliance with French regulations. The Regional Committee on Animal 
Experimentation approved this study. STLV-1 infection was initially determined by 
serological methods and confirmed by PCR (data not shown). Three animals were left 
untreated, four animals received VPA alone (Depakine chrono, Sanofi Aventis, France; 
500mg/day), two animals received AZT alone (Retrovir, GlaxoSmithKline, UK; 300mg/day) 
and five received a combination of both drugs (Table 1). The drugs were given per os 
(embedded in food such as bananas) to each baboon on a daily basis. In all cases, 
veterinarians ascertained that the drug had been eaten. This was also confirmed by measuring 
the VPA serum levels for each blood sample, using a routine diagnostic method (data not 
shown). Treatment toxicity was monitored by behavioral observations, regular weight 
measurement and transaminase blood level assessment – (aspartate aminotransferase and 
alanine aminotransferase) (data not shown). The treatment lasted two months. Peripheral 
venous blood samples from 5 non-infected baboons were also collected in order to compare 
the initial immune activation level between STLV+ and STLV- animals. 
PBMCs were purified by Ficoll gradient centrifugation from heparin-anticoagulated 
peripheral venous blood.  
 
STLV-1 proviral load 
PBMCs were resuspended in lysis buffer (10 mM Tris–HCl (pH 8.0), 5 mM EDTA, 50 mM 
NaCl, 0.5% sodium dodecyl sulfate, and 200 µg/mL proteinase K) and incubated overnight at 
65°C. DNA was then purified by three consecutive extractions (phenol, phenol/chloroform, 
 7 
and chloroform). DNA was precipitated with isopropanol, washed with ethanol, and 
resuspended in polymerase chain reaction (PCR) grade water. The STLV-1 and albumin 
specific primers and PCR protocol were previously described 36. Real time PCR was carried 
out in a Roche light cycler by using the DyNamo Capillary SYBR Green qPCR kit 
(Finnzymes, FI) and the Light Cycler Taqman master mix (Roche Diagnostics, IN, USA). 
Standard curves were generated using serial dilutions of DNA from the MT-4 cell line (which 
carries 7 proviral copies). 
 
Flow cytometry 
Lymphocytes isolated from heparin-anticoagulated blood were stained with the following 
monoclonal antibodies: anti-CD3-PerCP (clone SP34-2; BD Biosciences, MA, USA), anti-
CD4-PerCP or -APC (clone L200; BD Biosciences), anti-CD8-PE or -APC (clone RPA-T8; 
BD Biosciences), anti-CD20-FITC (clone 2H7, BD biosciences), anti-CD45RA-FITC (clone 
5H9; BD biosciences), anti-CD27-RPE (clone M-T271), anti-CD28-FITC or -PE (clone 
CD2.8, BD biosciences), anti-CD95-PE or -APC (clone DX2, BD biosciences) and anti-Ki67-
FITC (clone MIB-1; DAKO, DK). 
For cell surface staining, antibodies were added to the PBMCs for 1 hour at 4°C. PBMCs 
were then fixed and permeabilized with 250 µl of Cytofix/Cytoperm (BD Biosciences) for 
intracellular staining. After washing with Perm&Wash (BD Biosciences), the cells were 
incubated for 1 hour with anti-Ki67 antibodies. After washing, the cells were analyzed by 
flow cytometry as previously described 37. A total of 20,000 events in the lymphocyte gate 
were analyzed using FlowJo software (TreeStar, Ashlan, OR, USA).  
Absolute numbers of lymphocytes in blood were ascertained using routine diagnostic counts. 
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Lytic efficiency assay 
The assay was performed with samples from four animals. The assay quantifies the rate of 
disappearance of CD4+ Tax-expressing cells caused by addition of autologous CD8+ cells 38. 
PBMCs were washed and the CD8+ cells positively selected with anti-CD8 (clone RPA-T8) 
coupled to magnetic microbeads (Miltenyi Biotec, Germany). The CD8+ cells were then 
titrated back into the CD8-depleted fraction from the same individual that had been isolated 
before treatment. Cells were then co-cultivated at 37°C for 18 hours, harvested, and stained 
for Tax 39, CD4, and CD8 as described above. The proportion of Tax+CD4+ cells surviving 
co-culture was plotted against the proportion of CD8+ cells present. The lytic efficient rate 
(percentage CD4+Tax+ cells killed/%CD8+ cells/day) was then calculated according to a 
previously described mathematical model 38. 
The assays were performed in duplicate and the results are presented as the mean CD8+ cell 
lytic rate ("efficiency").  
 
Statistical analysis 
Analyses were performed in PRISM v.5.0b. We used one-tailed paired Student's t-tests to 
compare results in paired samples and Mann-Whitney tests to compare unpaired groups. P 
values < 0.05 were considered significant. The non-linear regression presented in figure 5 was 
determined following a one-phase exponential decay model. 
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RESULTS 
STLV-1 infection is associated with changes in T-lymphocyte populations  
We initially compared the immunological profiles of asymptomatic infected (STLV-1+) and 
uninfected (STLV-1-) baboons. Infected baboons had a higher total number of T-lymphocytes 
(Mann-Whitney, p=0.005) (Figure 1A). However the ratio between CD4+ and CD8+ T-cells 
remained constant (Figure 1B). The viral infection also decreased the proportion of naïve 
(CD28+CD95-) CD8+ T-lymphocytes (Figure 1C, p=0.02, Mann-Whitney) and increased the 
proportion of CD28- (Mann-Whitney, p=0.008) and CD45RA- CD27+ (Mann-Whitney, 
p=0.007) CD8+ effector T-lymphocytes (Figure 1C-D). Similar differences in T-cell 
phenotypes were reported previously between uninfected humans and HAM/TSP patients 40. 
These results support the idea that the immune system of STLV-1 infected baboons is active 
but unable to clear the infection. 
 
The combination of VPA and AZT reduced the PVL in asymptomatic animals 
We then tested the effect of a treatment consisting of daily doses of VPA alone or in 
combination with AZT, given per os for 2 months to a series of male and female STLV-1 
infected baboons whose PVL was quantified before the initiation of the trial (Table 1). In the 
absence of treatment, STLV-1 PVL did not change during observation for 2 months (paired 
Student’s t test, p=0.27) (Figure 2, upper graph black lines). Consistent with previous HTLV-
1 reports 9,41,42, AZT had no impact on the PVL after 2 months of treatment (paired Student’s t 
test, p=0.11) (Figure 2, upper graph blue lines). As reported in HAM/TSP patients, VPA 
treatment induced a transient increase in the PVL during the first two weeks in 3 animals out 
of 4. However, and contrary to what was previously reported 9,32, treatment with VPA alone 
did not cause a significant reduction of the PVL in STLV-1 infected baboons after 2 months 
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of treatment (paired Student’s t test, p=0.3) (Figure 2, central panel, purple lines). Strikingly, 
the combined VPA/AZT treatment resulted in a 5- to 12-fold PVL reduction in the 3 animals 
with a PVL higher than 1 copy per 100 PBMCs. Crucially, the combined treatment prevented 
the transient increase in mean PVL that is seen after VPA alone (Figure 2, lower graph, 
orange lines). 
  
Combined treatment with VPA and AZT resulted in an accumulation of CD8+ 
lymphocytes  
Because the increase in PVL occurred in animals treated with VPA alone during the first 
week of treatment, we focused our immunological analyses on this period. There was no 
significant variation in the absolute number of T-cells either in control (untreated) or AZT-
treated animals (Figure 3A, upper row) during the first week of the trial (paired Student’s t-
test, p=0.9 and p=0.8 respectively). In all but one VPA-treated animals, the total T-cell 
number decreased especially for CD8+ T cells (paired Student’s t-test, p=0.045) (Figure 3A, 
central row). Interestingly, animal V2, which had no transient increase in PVL, also displayed 
an increased total lymphocyte number. Conversely, in the VPA-AZT treated animals, the 
decrease in PVL was associated with a significant increase in the number of lymphocytes 
(paired Student’s t-test, p=0.016), principally of the CD8+ T cell population (Figure 3A, lower 
row). In the 2 animals that did not display a major change in PVL following VPA/AZT 
treatment, the total lymphocyte count also remained approximately constant. 
 
Combined VPA/AZT treatment results in an accumulation of CD8+ effector 
lymphocytes  
In order to determine which T-cell subpopulations were altered during the treatment, naïve, 
central memory and effector CD8+ cell populations were analyzed one week post-initiation of 
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the treatment using two sets of markers: CD28/CD95 (figure 3B) and CD45RA/CD27 
(Supplemental Figure 1). The numbers of CD28+CD95- (naïve) and CD28+CD95+ (central 
memory) CD8+ T-cells were unchanged in all four groups of animals (Kruskal-Wallis, p=0.43 
and 0.62 respectively). However, significant changes were observed in the CD8+ CD28- 
(effector) T-cell population (Figure 3B, right panels). The animals treated with VPA had a 
decrease in the number of CD8+ CD28- (effector) T cells (paired Student’s t-test, p=0.039), 
with the exception of the animal V2. In the VPA/AZT-treated animals, whose PVL decreased 
upon treatment, the number of effector CD8+ CD28- T cells increased (paired Student’s t-test, 
p=0.039). This result was confirmed with the second set of differentiation markers: the CD8+ 
T cell population whose number fluctuated was mainly CD45RA-CD27- (effector memory) 
(paired-Student’s t-test, p=0.02 and 0.036 for VPA and VPA/AZT respectively) 
(Supplemental figure 1). In contrast, the CD4+ T-cell count was not altered (Supplemental 
Figure 2). 
To determine the origin of the CD8+ population expansion, lymphocyte proliferation was 
quantified by analysis of Ki67 expression (Figure 4). The proportion of proliferating CD4+ 
cells was not modified in untreated, AZT-treated or VPA-treated monkeys (data not show), 
although a rebound in viral replication was observed in this latter group at 1 week of 
treatment. This observation strongly suggests that the transient PVL increase observed during 
VPA treatment is the consequence of new cycles of infection within the PBMCs. Conversely, 
the accumulation of effector CD8+ T-lymphocytes (CD28-) in VPA/AZT-treated animals was 
associated with an increase in proliferation of the CD8+ central memory T-cell 
(CD28+CD95+) subset (paired Student’s t-test, p=0.035) (Figure 4, central panel), consistent 
with the normal pathway of T-cell differentiation.  
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STLV-1 PVL reduction correlated with an accumulation of anti-retroviral cytotoxic 
lymphocytes  
We determined whether the accumulation of effector CD8+ T-cells in VPA/AZT treated 
monkeys represented an increase in the population of cytotoxic lymphocytes (CTL) directed 
against STLV-1. To this end, we determined the rate of CD8+-mediated lysis of autologous, 
naturally STLV-1-infected cells at different time points (days 0, 7 and 15 of treatment). The 
results revealed a correlation between the variation in the CD8+ cell-mediated lysis rate and 
the variation in STLV-1 PVL (Figure 5). 
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DISCUSSION 
 We analyzed the impact of a combination of valproate (VPA), an inhibitor of histone 
deacetylases (HDACi), and AZT, an inhibitor of the reverse transcriptase, in asymptomatic 
baboons naturally infected with Simian T-Lymphotropic Virus type 1 (STLV-1).  
These non-human primates constitute the best model for studying HTLV-1 associated 
diseases and potential therapies, since baboons are the natural hosts for STLV-1, a retrovirus 
closely related to HTLV-1. In simians, as in humans, the infection remains mainly 
asymptomatic. However, cases of ATLL-like retrovirus-associated diseases have been 
reported 35. We show here that the differences in the T-lymphocyte subpopulations associated 
with STLV-1 infection in baboons are also similar to those described in HTLV-1-infected 
humans 40. In each case, the retroviral infection is associated with an accumulation of effector 
T-lymphocytes, which represent a marker of an immune response against the virus. One 
means of retroviral escape from the immune response is proviral silencing through epigenetic 
regulation. This is the reason why we hypothesized that drug-induced viral activation would 
promote viral clearance by the immune system. 
A previous study described the use of VPA in HAM/TSP patients, which resulted in a 
significant decrease in the PVL after 45-60 days of treatment 9. We therefore hypothesized 
that VPA-based treatments could be given to ACs at risk of developing an HTLV-1 associated 
disease. Surprisingly, in our assay, administration of VPA alone did not cause any reduction 
in PVL during 2 months of treatment. However, and consistent with the previous report9, we 
observe a transient but significant (up to a 3-fold increase) rise in PVL during the first week 
of treatment, suggesting that VPA treatment is not only unsuccessful, but might be hazardous 
by increasing the rate at which HTLV-1-infected lymphocytes cross the blood-brain barrier, 
as suggested previously 32. 
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In contrast, the VPA/AZT combination prevented the transient rise in PVL caused by VPA 
alone. More interestingly, it also induced a significant reduction in PVL in animals with a 
high initial PVL. The decrease in PVL was associated with an accumulation of effector CD8+ 
T-lymphocytes and cytolytic lymphocytes directed against the virus. This strongly suggests 
that the observed PVL decrease was not due to a direct apoptotic effect of the VPA on 
infected cells, as suggested by in vitro studies 30,31, but rather to an increase in the 
effectiveness of the anti-STLV-1 cellular immune response. The accumulation of CTL is a 
consequence of an increased proliferation of memory CD8+ T-cells. The proliferation of 
memory cells and subsequent accumulation of effector cells was not seen in the VPA group. 
We therefore suggest that the observed reduction in PVL was caused by an efficient immune 
response against the virus when de novo infection was prevented by addition of AZT. Our 
current working model is the following: in VPA/AZT treated animals, infected cells express 
the virus in response to VPA treatment. When central memory lymphocytes recognize these 
cells, they proliferate, differentiate into effector cells, and kill STLV-1 infected cells, which 
leads to a decrease in PVL. On the contrary, in the absence of AZT, the virus spreads, STLV-
1-specific central memory cells become infected, and are destroyed by autologous CD8+ T 
cells in a ‘fratricidal’ response 13. Thus, the number of proliferating virus-specific memory 
cells decreases, and cannot reconstitute the effector CD8+ reservoir. As a result, the PVL may 
increase.  
 As stated above, the proviral load is the strongest known correlate of inflammatory 
diseases in HTLV-1 infection. However, the only described therapy that reduces the PVL 
causes a large initial transient rise before the eventual fall 9. Our present data represent 
therefore the first indication that it is possible to make a substantial reduction in the PVL of 
an oncogenic retrovirus without a concomitant significant rise in the PVL shortly after 
starting treatment. This suggests that, when biomarkers are available, VPA/AZT could be 
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given to HAM/TSP patients at the early stage of the disease. Finally, a recent nationwide 
prospective study conducted in Japan strongly suggested that a higher PVL is a strong factor 
in the development of ATLL 43. The VPA/AZT combination may therefore be used as a 
preventive treatment for other HTLV-1 related diseases such as ATLL.  
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Table 1: Experimental protocol.  
Fifteen STLV-1 infected Papio papio were given daily a dose of VPA and/or AZT per os. 
The STLV-1 proviral load values are presented as the Tax copy number per 105 PBMCs at the 
initiation of the treatment. These values were also determined a month before the initiation of 
the trial and were found to be similar. 
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Figure 1: STLV-1 infection induces a constitutive activation of the simian immune 
system. 
 (A) Comparison of the CD3+ cell number per mm3 of blood between non-infected (5 
animals) and STLV-1 infected (15 animals) monkeys before initiation of the treatment. Cells 
were stained with CD3 antibodies. The percentages obtained were then reported to the total 
lymphocyte number determined by clinical automated lymphocyte count.  
(B) Comparison of T-CD4+/T-CD8+ ratio between non-infected and infected monkeys before 
treatment. Cells were stained with CD4, CD8 and CD3 antibodies.  
(C) Comparison of CD8+ subpopulations count per mm3 of blood determined before 
treatment. Cells were stained for CD3, CD8, CD95 and CD28. 
Significant differences (p<0.05) under Mann-Whitney tests are outlined with the asterisk. 
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Figure 2: Combined VPA/AZT treatment is linked to a significant reduction of the PVL 
in STLV-1 asymptomatic carriers.  
The PVL (copy number/105 PBMCs) was determined by real time PCR, as previously 
described 36. For a given individual, all samples were run at the same time, to avoid inter-
experiment variation. The values presented here are the mean of two independent assays. C: 
controls; A: AZT, V: valproate; VA: Valproate + AZT 
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Figure 3: VPA/AZT treatment to an accumulation of CD8+ effector memory T-
lymphocytes.  
(A) Variation of CD3+, CD4+ and CD8+ cell number per mm3 of blood was determined at day 
0 and 7 of treatment. Cells were stained with CD4, CD8 and CD3 antibodies and analyzed by 
flow cytometry. The absolute numbers are derived from the absolute lymphocyte count 
previously determined by clinical automated systems.  
(B) Variation in the CD8+ subpopulations count was determined at day 0 and 7 of treatment. 
Cells were stained for CD3, CD8, CD95 and CD28. 
Significant differences (p<0.05) under paired-Student’s t-tests are outlined with the asterisk. 
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Figure 4: VPA/AZT treatment induces a proliferation of CD8+ central memory T-
lymphocytes.  
Variations in Ki67 expression (a marker for cell proliferation) was determined within the 
CD8+ T-cells subpopulations. The cells were stained for CD8, CD28, CD95 and Ki67.  
Statistical differences (p<0.05) under paired-Student’s t-tests are outlined with the asterisk. 
 
 
 
 
 
Figure 5: STLV-1 PVL evolution is inversely correlated with the rate of CD8+ cell–
mediated lysis of STLV-1-infected cells. 
The lytic efficiency rates (or epsilon) were determined at different times (at 0, 1 and 2 weeks 
of treatment) for the 4 baboons, whose Tax-expression was detectable by flow cytometry in 
the PBMCs. The variations of the epsilon value over a time period of one week were plotted 
against the corresponding variations of PVL. The plot is overlaid with the line of best.  
The variations of PVL and epsilon correlate significantly according to a one-phase 
exponential decay model (R2= 0.63, or R2= 0.989 if the outlier point is excluded).  
 
 
  
 
 
